

Global Liposomal and Lipid-based Nanoparticle Drug Market Research Report 2023

<https://marketpublishers.com/r/GB35DE6DFA0FEN.html>

Date: December 2023

Pages: 107

Price: US\$ 2,900.00 (Single User License)

ID: GB35DE6DFA0FEN

Abstracts

Nanoparticle drug delivery systems are engineered technologies that use nanoparticles for the targeted delivery and controlled release of therapeutic agents. The modern form of a drug delivery system should minimize side-effects and reduce both dosage and dosage frequency. Recently, nanoparticles have aroused attention due to their potential application for effective drug delivery.

According to QYResearch's new survey, global Liposomal and Lipid-based Nanoparticle Drug market is projected to reach US\$ 9855.2 million in 2029, increasing from US\$ 5019 million in 2022, with the CAGR of 10.0% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Liposomal and Lipid-based Nanoparticle Drug market research.

The liposomes nanoparticle drugs market is driven by the increasing demand for targeted drug delivery systems and the potential of liposomes to improve therapeutic efficacy. Liposomes are nanoscale vesicles composed of lipid bilayers that can encapsulate various drugs and deliver them to specific target sites in the body. This targeted drug delivery offers benefits such as reduced side effects, improved drug bioavailability, and enhanced therapeutic outcomes. As the prevalence of chronic diseases rises and the need for personalized medicine grows, liposomes nanoparticle drugs gain popularity in the pharmaceutical industry. Moreover, advancements in nanotechnology and biopharmaceutical research have led to the development of innovative liposomal formulations for a wide range of diseases. However, the market also faces challenges, including the high costs associated with liposomal drug development and production. Additionally, regulatory complexities related to

nanomedicines and the need for comprehensive safety evaluations pose obstacles to market growth. To leverage the market's potential fully, manufacturers need to focus on cost-effectiveness, quality assurance, and robust clinical data to gain regulatory approvals and establish the efficacy and safety of liposomes nanoparticle drugs.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Liposomal and Lipid-based Nanoparticle Drug market with multiple angles, which provides sufficient supports to readers' strategy and decision making.

By Company

Johnson & Johnson

Sun Pharmaceutical

CSPC

Kinyond

Teva

Fudan-Zhangjiang

Zydus Cadila

TTY Biopharma

Pacira

Luye Pharma

Leadiant Biosciences

Ipsen

Sayre Therapeutics

Jazz

Alnylam

Bausch Health

Acrotech Biopharma

Takeda

Chiesi Farmaceutici

Gilead Sciences

Segment by Type

Liposomes Drugs

Lipid Nanoparticle Drugs

Segment by Application

Hospital

Retail Pharmacy

Other

By Region

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

The Liposomal and Lipid-based Nanoparticle Drug report covers below items:

Chapter 1: Product Basic Information (Definition, Type and Application)

Chapter 2: Global market size, regional market size. Market Opportunities and Challenges

Chapter 3: Companies' Competition Patterns

Chapter 4: Product Type Analysis

Chapter 5: Product Application Analysis

Chapter 6 to 10: Country Level Value Analysis

Chapter 11: Companies' Outline

Chapter 12: Market Conclusions

Chapter 13: Research Methodology and Data Source

Contents

1 REPORT OVERVIEW

- 1.1 Study Scope
- 1.2 Market Analysis by Type
 - 1.2.1 Global Liposomal and Lipid-based Nanoparticle Drug Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
 - 1.2.2 Liposomes Drugs
 - 1.2.3 Lipid Nanoparticle Drugs
- 1.3 Market by Application
 - 1.3.1 Global Liposomal and Lipid-based Nanoparticle Drug Market Growth by Application: 2018 VS 2022 VS 2029
 - 1.3.2 Hospital
 - 1.3.3 Retail Pharmacy
 - 1.3.4 Other
- 1.4 Study Objectives
- 1.5 Years Considered
- 1.6 Years Considered

2 GLOBAL GROWTH TRENDS

- 2.1 Global Liposomal and Lipid-based Nanoparticle Drug Market Perspective (2018-2029)
- 2.2 Liposomal and Lipid-based Nanoparticle Drug Growth Trends by Region
 - 2.2.1 Global Liposomal and Lipid-based Nanoparticle Drug Market Size by Region: 2018 VS 2022 VS 2029
 - 2.2.2 Liposomal and Lipid-based Nanoparticle Drug Historic Market Size by Region (2018-2023)
 - 2.2.3 Liposomal and Lipid-based Nanoparticle Drug Forecasted Market Size by Region (2024-2029)
- 2.3 Liposomal and Lipid-based Nanoparticle Drug Market Dynamics
 - 2.3.1 Liposomal and Lipid-based Nanoparticle Drug Industry Trends
 - 2.3.2 Liposomal and Lipid-based Nanoparticle Drug Market Drivers
 - 2.3.3 Liposomal and Lipid-based Nanoparticle Drug Market Challenges
 - 2.3.4 Liposomal and Lipid-based Nanoparticle Drug Market Restraints

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Liposomal and Lipid-based Nanoparticle Drug Players by Revenue

3.1.1 Global Top Liposomal and Lipid-based Nanoparticle Drug Players by Revenue (2018-2023)

3.1.2 Global Liposomal and Lipid-based Nanoparticle Drug Revenue Market Share by Players (2018-2023)

3.2 Global Liposomal and Lipid-based Nanoparticle Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Liposomal and Lipid-based Nanoparticle Drug Revenue

3.4 Global Liposomal and Lipid-based Nanoparticle Drug Market Concentration Ratio

3.4.1 Global Liposomal and Lipid-based Nanoparticle Drug Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Liposomal and Lipid-based Nanoparticle Drug Revenue in 2022

3.5 Liposomal and Lipid-based Nanoparticle Drug Key Players Head office and Area Served

3.6 Key Players Liposomal and Lipid-based Nanoparticle Drug Product Solution and Service

3.7 Date of Enter into Liposomal and Lipid-based Nanoparticle Drug Market

3.8 Mergers & Acquisitions, Expansion Plans

4 LIPOSOMAL AND LIPID-BASED NANOPARTICLE DRUG BREAKDOWN DATA BY TYPE

4.1 Global Liposomal and Lipid-based Nanoparticle Drug Historic Market Size by Type (2018-2023)

4.2 Global Liposomal and Lipid-based Nanoparticle Drug Forecasted Market Size by Type (2024-2029)

5 LIPOSOMAL AND LIPID-BASED NANOPARTICLE DRUG BREAKDOWN DATA BY APPLICATION

5.1 Global Liposomal and Lipid-based Nanoparticle Drug Historic Market Size by Application (2018-2023)

5.2 Global Liposomal and Lipid-based Nanoparticle Drug Forecasted Market Size by Application (2024-2029)

6 NORTH AMERICA

6.1 North America Liposomal and Lipid-based Nanoparticle Drug Market Size (2018-2029)

6.2 North America Liposomal and Lipid-based Nanoparticle Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029

6.3 North America Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2018-2023)

6.4 North America Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2024-2029)

6.5 United States

6.6 Canada

7 EUROPE

7.1 Europe Liposomal and Lipid-based Nanoparticle Drug Market Size (2018-2029)

7.2 Europe Liposomal and Lipid-based Nanoparticle Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029

7.3 Europe Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2018-2023)

7.4 Europe Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2024-2029)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 ASIA-PACIFIC

8.1 Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size (2018-2029)

8.2 Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Growth Rate by Region: 2018 VS 2022 VS 2029

8.3 Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size by Region (2018-2023)

8.4 Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size by Region (2024-2029)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 LATIN AMERICA

9.1 Latin America Liposomal and Lipid-based Nanoparticle Drug Market Size (2018-2029)

9.2 Latin America Liposomal and Lipid-based Nanoparticle Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029

9.3 Latin America Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2018-2023)

9.4 Latin America Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2024-2029)

9.5 Mexico

9.6 Brazil

10 MIDDLE EAST & AFRICA

10.1 Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size (2018-2029)

10.2 Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029

10.3 Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2018-2023)

10.4 Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2024-2029)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 KEY PLAYERS PROFILES

11.1 Johnson & Johnson

11.1.1 Johnson & Johnson Company Detail

11.1.2 Johnson & Johnson Business Overview

11.1.3 Johnson & Johnson Liposomal and Lipid-based Nanoparticle Drug Introduction

11.1.4 Johnson & Johnson Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2018-2023)

- 11.1.5 Johnson & Johnson Recent Development
- 11.2 Sun Pharmaceutical
 - 11.2.1 Sun Pharmaceutical Company Detail
 - 11.2.2 Sun Pharmaceutical Business Overview
 - 11.2.3 Sun Pharmaceutical Liposomal and Lipid-based Nanoparticle Drug Introduction
 - 11.2.4 Sun Pharmaceutical Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2018-2023)
 - 11.2.5 Sun Pharmaceutical Recent Development
- 11.3 CSPC
 - 11.3.1 CSPC Company Detail
 - 11.3.2 CSPC Business Overview
 - 11.3.3 CSPC Liposomal and Lipid-based Nanoparticle Drug Introduction
 - 11.3.4 CSPC Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2018-2023)
 - 11.3.5 CSPC Recent Development
- 11.4 Kinyond
 - 11.4.1 Kinyond Company Detail
 - 11.4.2 Kinyond Business Overview
 - 11.4.3 Kinyond Liposomal and Lipid-based Nanoparticle Drug Introduction
 - 11.4.4 Kinyond Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2018-2023)
 - 11.4.5 Kinyond Recent Development
- 11.5 Teva
 - 11.5.1 Teva Company Detail
 - 11.5.2 Teva Business Overview
 - 11.5.3 Teva Liposomal and Lipid-based Nanoparticle Drug Introduction
 - 11.5.4 Teva Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2018-2023)
 - 11.5.5 Teva Recent Development
- 11.6 Fudan-Zhangjiang
 - 11.6.1 Fudan-Zhangjiang Company Detail
 - 11.6.2 Fudan-Zhangjiang Business Overview
 - 11.6.3 Fudan-Zhangjiang Liposomal and Lipid-based Nanoparticle Drug Introduction
 - 11.6.4 Fudan-Zhangjiang Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2018-2023)
 - 11.6.5 Fudan-Zhangjiang Recent Development
- 11.7 Zydus Cadila
 - 11.7.1 Zydus Cadila Company Detail
 - 11.7.2 Zydus Cadila Business Overview

- 11.7.3 Zydus Cadila Liposomal and Lipid-based Nanoparticle Drug Introduction
- 11.7.4 Zydus Cadila Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2018-2023)
- 11.7.5 Zydus Cadila Recent Development
- 11.8 TTY Biopharma
 - 11.8.1 TTY Biopharma Company Detail
 - 11.8.2 TTY Biopharma Business Overview
 - 11.8.3 TTY Biopharma Liposomal and Lipid-based Nanoparticle Drug Introduction
 - 11.8.4 TTY Biopharma Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2018-2023)
 - 11.8.5 TTY Biopharma Recent Development
- 11.9 Pacira
 - 11.9.1 Pacira Company Detail
 - 11.9.2 Pacira Business Overview
 - 11.9.3 Pacira Liposomal and Lipid-based Nanoparticle Drug Introduction
 - 11.9.4 Pacira Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2018-2023)
 - 11.9.5 Pacira Recent Development
- 11.10 Luye Pharma
 - 11.10.1 Luye Pharma Company Detail
 - 11.10.2 Luye Pharma Business Overview
 - 11.10.3 Luye Pharma Liposomal and Lipid-based Nanoparticle Drug Introduction
 - 11.10.4 Luye Pharma Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2018-2023)
 - 11.10.5 Luye Pharma Recent Development
- 11.11 Leadiant Biosciences
 - 11.11.1 Leadiant Biosciences Company Detail
 - 11.11.2 Leadiant Biosciences Business Overview
 - 11.11.3 Leadiant Biosciences Liposomal and Lipid-based Nanoparticle Drug Introduction
 - 11.11.4 Leadiant Biosciences Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2018-2023)
 - 11.11.5 Leadiant Biosciences Recent Development
- 11.12 Ipsen
 - 11.12.1 Ipsen Company Detail
 - 11.12.2 Ipsen Business Overview
 - 11.12.3 Ipsen Liposomal and Lipid-based Nanoparticle Drug Introduction
 - 11.12.4 Ipsen Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2018-2023)

- 11.12.5 Ipsen Recent Development
- 11.13 Sayre Therapeutics
 - 11.13.1 Sayre Therapeutics Company Detail
 - 11.13.2 Sayre Therapeutics Business Overview
 - 11.13.3 Sayre Therapeutics Liposomal and Lipid-based Nanoparticle Drug Introduction
 - 11.13.4 Sayre Therapeutics Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2018-2023)
 - 11.13.5 Sayre Therapeutics Recent Development
- 11.14 Jazz
 - 11.14.1 Jazz Company Detail
 - 11.14.2 Jazz Business Overview
 - 11.14.3 Jazz Liposomal and Lipid-based Nanoparticle Drug Introduction
 - 11.14.4 Jazz Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2018-2023)
 - 11.14.5 Jazz Recent Development
- 11.15 Alnylam
 - 11.15.1 Alnylam Company Detail
 - 11.15.2 Alnylam Business Overview
 - 11.15.3 Alnylam Liposomal and Lipid-based Nanoparticle Drug Introduction
 - 11.15.4 Alnylam Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2018-2023)
 - 11.15.5 Alnylam Recent Development
- 11.16 Bausch Health
 - 11.16.1 Bausch Health Company Detail
 - 11.16.2 Bausch Health Business Overview
 - 11.16.3 Bausch Health Liposomal and Lipid-based Nanoparticle Drug Introduction
 - 11.16.4 Bausch Health Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2018-2023)
 - 11.16.5 Bausch Health Recent Development
- 11.17 Acrotech Biopharma
 - 11.17.1 Acrotech Biopharma Company Detail
 - 11.17.2 Acrotech Biopharma Business Overview
 - 11.17.3 Acrotech Biopharma Liposomal and Lipid-based Nanoparticle Drug Introduction
 - 11.17.4 Acrotech Biopharma Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2018-2023)
 - 11.17.5 Acrotech Biopharma Recent Development
- 11.18 Takeda
 - 11.18.1 Takeda Company Detail

- 11.18.2 Takeda Business Overview
- 11.18.3 Takeda Liposomal and Lipid-based Nanoparticle Drug Introduction
- 11.18.4 Takeda Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2018-2023)
- 11.18.5 Takeda Recent Development
- 11.19 Chiesi Farmaceutici
 - 11.19.1 Chiesi Farmaceutici Company Detail
 - 11.19.2 Chiesi Farmaceutici Business Overview
 - 11.19.3 Chiesi Farmaceutici Liposomal and Lipid-based Nanoparticle Drug Introduction
 - 11.19.4 Chiesi Farmaceutici Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2018-2023)
 - 11.19.5 Chiesi Farmaceutici Recent Development
- 11.20 Gilead Sciences
 - 11.20.1 Gilead Sciences Company Detail
 - 11.20.2 Gilead Sciences Business Overview
 - 11.20.3 Gilead Sciences Liposomal and Lipid-based Nanoparticle Drug Introduction
 - 11.20.4 Gilead Sciences Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2018-2023)
 - 11.20.5 Gilead Sciences Recent Development

12 ANALYST'S VIEWPOINTS/CONCLUSIONS

13 APPENDIX

- 13.1 Research Methodology
 - 13.1.1 Methodology/Research Approach
 - 13.1.2 Data Source
- 13.2 Disclaimer
- 13.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Global Liposomal and Lipid-based Nanoparticle Drug Market Size Growth Rate by Type (US\$ Million): 2018 VS 2022 VS 2029

Table 2. Key Players of Liposomes Drugs

Table 3. Key Players of Lipid Nanoparticle Drugs

Table 4. Global Liposomal and Lipid-based Nanoparticle Drug Market Size Growth by Application (US\$ Million): 2018 VS 2022 VS 2029

Table 5. Global Liposomal and Lipid-based Nanoparticle Drug Market Size by Region (US\$ Million): 2018 VS 2022 VS 2029

Table 6. Global Liposomal and Lipid-based Nanoparticle Drug Market Size by Region (2018-2023) & (US\$ Million)

Table 7. Global Liposomal and Lipid-based Nanoparticle Drug Market Share by Region (2018-2023)

Table 8. Global Liposomal and Lipid-based Nanoparticle Drug Forecasted Market Size by Region (2024-2029) & (US\$ Million)

Table 9. Global Liposomal and Lipid-based Nanoparticle Drug Market Share by Region (2024-2029)

Table 10. Liposomal and Lipid-based Nanoparticle Drug Market Trends

Table 11. Liposomal and Lipid-based Nanoparticle Drug Market Drivers

Table 12. Liposomal and Lipid-based Nanoparticle Drug Market Challenges

Table 13. Liposomal and Lipid-based Nanoparticle Drug Market Restraints

Table 14. Global Liposomal and Lipid-based Nanoparticle Drug Revenue by Players (2018-2023) & (US\$ Million)

Table 15. Global Liposomal and Lipid-based Nanoparticle Drug Market Share by Players (2018-2023)

Table 16. Global Top Liposomal and Lipid-based Nanoparticle Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Liposomal and Lipid-based Nanoparticle Drug as of 2022)

Table 17. Ranking of Global Top Liposomal and Lipid-based Nanoparticle Drug Companies by Revenue (US\$ Million) in 2022

Table 18. Global 5 Largest Players Market Share by Liposomal and Lipid-based Nanoparticle Drug Revenue (CR5 and HHI) & (2018-2023)

Table 19. Key Players Headquarters and Area Served

Table 20. Key Players Liposomal and Lipid-based Nanoparticle Drug Product Solution and Service

Table 21. Date of Enter into Liposomal and Lipid-based Nanoparticle Drug Market

Table 22. Mergers & Acquisitions, Expansion Plans

Table 23. Global Liposomal and Lipid-based Nanoparticle Drug Market Size by Type (2018-2023) & (US\$ Million)

Table 24. Global Liposomal and Lipid-based Nanoparticle Drug Revenue Market Share by Type (2018-2023)

Table 25. Global Liposomal and Lipid-based Nanoparticle Drug Forecasted Market Size by Type (2024-2029) & (US\$ Million)

Table 26. Global Liposomal and Lipid-based Nanoparticle Drug Revenue Market Share by Type (2024-2029)

Table 27. Global Liposomal and Lipid-based Nanoparticle Drug Market Size by Application (2018-2023) & (US\$ Million)

Table 28. Global Liposomal and Lipid-based Nanoparticle Drug Revenue Market Share by Application (2018-2023)

Table 29. Global Liposomal and Lipid-based Nanoparticle Drug Forecasted Market Size by Application (2024-2029) & (US\$ Million)

Table 30. Global Liposomal and Lipid-based Nanoparticle Drug Revenue Market Share by Application (2024-2029)

Table 31. North America Liposomal and Lipid-based Nanoparticle Drug Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 32. North America Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2018-2023) & (US\$ Million)

Table 33. North America Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2024-2029) & (US\$ Million)

Table 34. Europe Liposomal and Lipid-based Nanoparticle Drug Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 35. Europe Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2018-2023) & (US\$ Million)

Table 36. Europe Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2024-2029) & (US\$ Million)

Table 37. Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size Growth Rate by Region (US\$ Million): 2018 VS 2022 VS 2029

Table 38. Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size by Region (2018-2023) & (US\$ Million)

Table 39. Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size by Region (2024-2029) & (US\$ Million)

Table 40. Latin America Liposomal and Lipid-based Nanoparticle Drug Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 41. Latin America Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2018-2023) & (US\$ Million)

Table 42. Latin America Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2024-2029) & (US\$ Million)

Table 43. Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 44. Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2018-2023) & (US\$ Million)

Table 45. Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2024-2029) & (US\$ Million)

Table 46. Johnson & Johnson Company Detail

Table 47. Johnson & Johnson Business Overview

Table 48. Johnson & Johnson Liposomal and Lipid-based Nanoparticle Drug Product

Table 49. Johnson & Johnson Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2018-2023) & (US\$ Million)

Table 50. Johnson & Johnson Recent Development

Table 51. Sun Pharmaceutical Company Detail

Table 52. Sun Pharmaceutical Business Overview

Table 53. Sun Pharmaceutical Liposomal and Lipid-based Nanoparticle Drug Product

Table 54. Sun Pharmaceutical Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2018-2023) & (US\$ Million)

Table 55. Sun Pharmaceutical Recent Development

Table 56. CSPC Company Detail

Table 57. CSPC Business Overview

Table 58. CSPC Liposomal and Lipid-based Nanoparticle Drug Product

Table 59. CSPC Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2018-2023) & (US\$ Million)

Table 60. CSPC Recent Development

Table 61. Kinyond Company Detail

Table 62. Kinyond Business Overview

Table 63. Kinyond Liposomal and Lipid-based Nanoparticle Drug Product

Table 64. Kinyond Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2018-2023) & (US\$ Million)

Table 65. Kinyond Recent Development

Table 66. Teva Company Detail

Table 67. Teva Business Overview

Table 68. Teva Liposomal and Lipid-based Nanoparticle Drug Product

Table 69. Teva Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2018-2023) & (US\$ Million)

Table 70. Teva Recent Development

Table 71. Fudan-Zhangjiang Company Detail

- Table 72. Fudan-Zhangjiang Business Overview
- Table 73. Fudan-Zhangjiang Liposomal and Lipid-based Nanoparticle Drug Product
- Table 74. Fudan-Zhangjiang Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2018-2023) & (US\$ Million)
- Table 75. Fudan-Zhangjiang Recent Development
- Table 76. Zydus Cadila Company Detail
- Table 77. Zydus Cadila Business Overview
- Table 78. Zydus Cadila Liposomal and Lipid-based Nanoparticle Drug Product
- Table 79. Zydus Cadila Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2018-2023) & (US\$ Million)
- Table 80. Zydus Cadila Recent Development
- Table 81. TTY Biopharma Company Detail
- Table 82. TTY Biopharma Business Overview
- Table 83. TTY Biopharma Liposomal and Lipid-based Nanoparticle Drug Product
- Table 84. TTY Biopharma Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2018-2023) & (US\$ Million)
- Table 85. TTY Biopharma Recent Development
- Table 86. Pacira Company Detail
- Table 87. Pacira Business Overview
- Table 88. Pacira Liposomal and Lipid-based Nanoparticle Drug Product
- Table 89. Pacira Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2018-2023) & (US\$ Million)
- Table 90. Pacira Recent Development
- Table 91. Luye Pharma Company Detail
- Table 92. Luye Pharma Business Overview
- Table 93. Luye Pharma Liposomal and Lipid-based Nanoparticle Drug Product
- Table 94. Luye Pharma Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2018-2023) & (US\$ Million)
- Table 95. Luye Pharma Recent Development
- Table 96. Leadiant Biosciences Company Detail
- Table 97. Leadiant Biosciences Business Overview
- Table 98. Leadiant Biosciences Liposomal and Lipid-based Nanoparticle Drug Product
- Table 99. Leadiant Biosciences Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2018-2023) & (US\$ Million)
- Table 100. Leadiant Biosciences Recent Development
- Table 101. Ipsen Company Detail
- Table 102. Ipsen Business Overview
- Table 103. Ipsen Liposomal and Lipid-based Nanoparticle Drug Product
- Table 104. Ipsen Revenue in Liposomal and Lipid-based Nanoparticle Drug Business

(2018-2023) & (US\$ Million)

Table 105. Ipsen Recent Development

Table 106. Sayre Therapeutics Company Detail

Table 107. Sayre Therapeutics Business Overview

Table 108. Sayre Therapeutics Liposomal and Lipid-based Nanoparticle Drug Product

Table 109. Sayre Therapeutics Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2018-2023) & (US\$ Million)

Table 110. Sayre Therapeutics Recent Development

Table 111. Jazz Company Detail

Table 112. Jazz Business Overview

Table 113. Jazz Liposomal and Lipid-based Nanoparticle Drug Product

Table 114. Jazz Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2018-2023) & (US\$ Million)

Table 115. Jazz Recent Development

Table 116. Alnylam Company Detail

Table 117. Alnylam Business Overview

Table 118. Alnylam Liposomal and Lipid-based Nanoparticle Drug Product

Table 119. Alnylam Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2018-2023) & (US\$ Million)

Table 120. Alnylam Recent Development

Table 121. Bausch Health Company Detail

Table 122. Bausch Health Business Overview

Table 123. Bausch Health Liposomal and Lipid-based Nanoparticle Drug Product

Table 124. Bausch Health Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2018-2023) & (US\$ Million)

Table 125. Bausch Health Recent Development

Table 126. Acrotech Biopharma Company Detail

Table 127. Acrotech Biopharma Business Overview

Table 128. Acrotech Biopharma Liposomal and Lipid-based Nanoparticle Drug Product

Table 129. Acrotech Biopharma Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2018-2023) & (US\$ Million)

Table 130. Acrotech Biopharma Recent Development

Table 131. Takeda Company Detail

Table 132. Takeda Business Overview

Table 133. Takeda Liposomal and Lipid-based Nanoparticle Drug Product

Table 134. Takeda Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2018-2023) & (US\$ Million)

Table 135. Takeda Recent Development

Table 136. Chiesi Farmaceutici Company Detail

Table 137. Chiesi Farmaceutici Business Overview

Table 138. Chiesi Farmaceutici Liposomal and Lipid-based Nanoparticle Drug Product

Table 139. Chiesi Farmaceutici Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2018-2023) & (US\$ Million)

Table 140. Chiesi Farmaceutici Recent Development

Table 141. Gilead Sciences Company Detail

Table 142. Gilead Sciences Business Overview

Table 143. Gilead Sciences Liposomal and Lipid-based Nanoparticle Drug Product

Table 144. Gilead Sciences Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2018-2023) & (US\$ Million)

Table 145. Gilead Sciences Recent Development

Table 146. Research Programs/Design for This Report

Table 147. Key Data Information from Secondary Sources

Table 148. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global Liposomal and Lipid-based Nanoparticle Drug Market Size Comparison by Type (2023-2029) & (US\$ Million)

Figure 2. Global Liposomal and Lipid-based Nanoparticle Drug Market Share by Type: 2022 VS 2029

Figure 3. Liposomes Drugs Features

Figure 4. Lipid Nanoparticle Drugs Features

Figure 5. Global Liposomal and Lipid-based Nanoparticle Drug Market Size Comparison by Application (2023-2029) & (US\$ Million)

Figure 6. Global Liposomal and Lipid-based Nanoparticle Drug Market Share by Application: 2022 VS 2029

Figure 7. Hospital Case Studies

Figure 8. Retail Pharmacy Case Studies

Figure 9. Other Case Studies

Figure 10. Liposomal and Lipid-based Nanoparticle Drug Report Years Considered

Figure 11. Global Liposomal and Lipid-based Nanoparticle Drug Market Size (US\$ Million), Year-over-Year: 2018-2029

Figure 12. Global Liposomal and Lipid-based Nanoparticle Drug Market Size, (US\$ Million), 2018 VS 2022 VS 2029

Figure 13. Global Liposomal and Lipid-based Nanoparticle Drug Market Share by Region: 2022 VS 2029

Figure 14. Global Liposomal and Lipid-based Nanoparticle Drug Market Share by Players in 2022

Figure 15. Global Top Liposomal and Lipid-based Nanoparticle Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Liposomal and Lipid-based Nanoparticle Drug as of 2022)

Figure 16. The Top 10 and 5 Players Market Share by Liposomal and Lipid-based Nanoparticle Drug Revenue in 2022

Figure 17. North America Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 18. North America Liposomal and Lipid-based Nanoparticle Drug Market Share by Country (2018-2029)

Figure 19. United States Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 20. Canada Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 21. Europe Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 22. Europe Liposomal and Lipid-based Nanoparticle Drug Market Share by Country (2018-2029)

Figure 23. Germany Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 24. France Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 25. U.K. Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 26. Italy Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 27. Russia Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 28. Nordic Countries Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 29. Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 30. Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Share by Region (2018-2029)

Figure 31. China Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 32. Japan Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 33. South Korea Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 34. Southeast Asia Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 35. India Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 36. Australia Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 37. Latin America Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 38. Latin America Liposomal and Lipid-based Nanoparticle Drug Market Share by Country (2018-2029)

Figure 39. Mexico Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 40. Brazil Liposomal and Lipid-based Nanoparticle Drug Market Size YoY

Growth (2018-2029) & (US\$ Million)

Figure 41. Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 42. Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Share by Country (2018-2029)

Figure 43. Turkey Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 44. Saudi Arabia Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 45. Johnson & Johnson Revenue Growth Rate in Liposomal and Lipid-based Nanoparticle Drug Business (2018-2023)

Figure 46. Sun Pharmaceutical Revenue Growth Rate in Liposomal and Lipid-based Nanoparticle Drug Business (2018-2023)

Figure 47. CSPC Revenue Growth Rate in Liposomal and Lipid-based Nanoparticle Drug Business (2018-2023)

Figure 48. Kinyond Revenue Growth Rate in Liposomal and Lipid-based Nanoparticle Drug Business (2018-2023)

Figure 49. Teva Revenue Growth Rate in Liposomal and Lipid-based Nanoparticle Drug Business (2018-2023)

Figure 50. Fudan-Zhangjiang Revenue Growth Rate in Liposomal and Lipid-based Nanoparticle Drug Business (2018-2023)

Figure 51. Zydus Cadila Revenue Growth Rate in Liposomal and Lipid-based Nanoparticle Drug Business (2018-2023)

Figure 52. TTY Biopharma Revenue Growth Rate in Liposomal and Lipid-based Nanoparticle Drug Business (2018-2023)

Figure 53. Pacira Revenue Growth Rate in Liposomal and Lipid-based Nanoparticle Drug Business (2018-2023)

Figure 54. Luye Pharma Revenue Growth Rate in Liposomal and Lipid-based Nanoparticle Drug Business (2018-2023)

Figure 55. Lediant Biosciences Revenue Growth Rate in Liposomal and Lipid-based Nanoparticle Drug Business (2018-2023)

Figure 56. Ipsen Revenue Growth Rate in Liposomal and Lipid-based Nanoparticle Drug Business (2018-2023)

Figure 57. Sayre Therapeutics Revenue Growth Rate in Liposomal and Lipid-based Nanoparticle Drug Business (2018-2023)

Figure 58. Jazz Revenue Growth Rate in Liposomal and Lipid-based Nanoparticle Drug Business (2018-2023)

Figure 59. Alnylam Revenue Growth Rate in Liposomal and Lipid-based Nanoparticle Drug Business (2018-2023)

Figure 60. Bausch Health Revenue Growth Rate in Liposomal and Lipid-based Nanoparticle Drug Business (2018-2023)

Figure 61. Acrotech Biopharma Revenue Growth Rate in Liposomal and Lipid-based Nanoparticle Drug Business (2018-2023)

Figure 62. Takeda Revenue Growth Rate in Liposomal and Lipid-based Nanoparticle Drug Business (2018-2023)

Figure 63. Chiesi Farmaceutici Revenue Growth Rate in Liposomal and Lipid-based Nanoparticle Drug Business (2018-2023)

Figure 64. Gilead Sciences Revenue Growth Rate in Liposomal and Lipid-based Nanoparticle Drug Business (2018-2023)

Figure 65. Bottom-up and Top-down Approaches for This Report

Figure 66. Data Triangulation

Figure 67. Key Executives Interviewed

I would like to order

Product name: Global Liposomal and Lipid-based Nanoparticle Drug Market Research Report 2023

Product link: <https://marketpublishers.com/r/GB35DE6DFA0FEN.html>

Price: US\$ 2,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GB35DE6DFA0FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970